Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

February 24, 2026

Pharmaceuticals

Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL
February 10, 2026

R & D

RGX-121: REGENXBIO received Complete Response Letter from the U.S. FDA for Biologics License Application for mucopolysaccharidosis type II
February 09, 2026

Corporate

Notice Regarding Executive Personnel Changes
February 09, 2026

Management & Finance

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025

Upcoming Events

March 02, 2026
R&D Meeting
February 09, 2026
IR Meeting (Q3/FY2025)
February 09, 2026
FY2025 3rd Qtr Results Announcement
November 14, 2025
IR Meeting(Q2/FY2025)
November 14, 2025
FY2025 2nd Qtr results announcement

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

February 1-28, 2026

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors